A randomized controlled clinical trial revealed that Dahuang Zhechong Pill modulates immune function in NAFLD patients primarily by reducing the Th17/Treg cell ratio and decreasing serum levels of pro-inflammatory cytokines, including interleukin-17 (IL-17), high-sensitivity C-reactive protein (hs-CRP), and TNF-α [173]. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.